---
layout: default
title: Zinc Gluconate
parent: 僅模型預測 (L5)
nav_order: 1076
evidence_level: L5
indication_count: 10
---

# Zinc Gluconate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Zinc Gluconate: From Zinc Supplementation to Anemia Of Prematurity

## One-Sentence Summary

> Zinc gluconate is a mineral supplement whose formal registered indication is not available in the current Singapore regulatory dataset.
> The TxGNN model predicts it may be effective for **Anemia of Prematurity**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a pure knowledge-graph signal with no direct evidence.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no Singapore registration record found (drug is not currently marketed) |
| Predicted New Indication | Anemia of Prematurity |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available for zinc gluconate. Based on general pharmacological knowledge, zinc is a cofactor for numerous enzymes relevant to red blood cell physiology (e.g., carbonic anhydrase, superoxide dismutase), which could theoretically intersect with pathways involved in erythropoiesis and premature infant hematology.

However, per the model's own rationale: *"Zinc is a cofactor for multiple enzymes related to erythropoiesis (e.g., carbonic anhydrase, SOD), and theoretically may influence hematopoietic function, but no clinical trial or literature directly supports zinc gluconate for anemia of prematurity. The high TxGNN score merely reflects topological proximity between zinc and blood-system nodes in the knowledge graph, not mechanistic evidence."*

This candidate should therefore be treated as a hypothesis-generating signal only, not as a mechanistically or clinically substantiated repurposing opportunity.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Zinc gluconate has no active Singapore registration records (0 licenses on file); the product is currently listed as not marketed.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction for anemia of prematurity is evidence level L5 (model prediction only) — there are zero clinical trials and zero publications, and the mechanistic link is acknowledged by the model itself as unsubstantiated topological proximity rather than real biological evidence.

**To proceed, the following is needed:**
- Mechanism of action (MOA) data from DrugBank (currently a blocking data gap, DG002)
- Regulatory safety label/warnings and contraindications data (blocking data gap DG001 — needed before any S1 safety assessment)
- Preclinical or clinical studies specifically evaluating zinc supplementation in anemia of prematurity
- Singapore market/registration data, since the drug is currently not marketed locally

**Note:** Among the 10 candidates generated for this drug, rank #2 ("injury," evidence level L3, decision stage S1, recommendation "Research Question") has substantially more supporting evidence, including an RCT on zinc + vitamin C in COVID-19 patients (NCT04558424) and multiple animal/mechanistic studies on tissue-protective effects. If prioritizing this drug for further review, the "injury" indication is a more evidence-backed starting point than "anemia of prematurity."
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

